Literature DB >> 20644255

Modeling metastasis biology and therapy in real time in the mouse lung.

Arnulfo Mendoza1, Sung-Hyeok Hong, Tanasa Osborne, Mohammed A Khan, Kirk Campbell, Joseph Briggs, Ananth Eleswarapu, Lauren Buquo, Ling Ren, Stephen M Hewitt, El Habib Dakir, El-H Dakir, Susan Garfield, Renard Walker, Glenn Merlino, Jeffrey E Green, Kent W Hunter, Lalage M Wakefield, Chand Khanna.   

Abstract

Pulmonary metastasis remains the leading ca use of death for cancer patients. Opportunities to improve treatment outcomes for patients require new methods to study and view the biology of metastatic progression. Here, we describe an ex vivo pulmonary metastasis assay (PuMA) in which the metastatic progression of GFP-expressing cancer cells, from a single cell to the formation of multicellular colonies, in the mouse lung microenvironment was assessed in real time for up to 21 days. The biological validity of this assay was confirmed by its prediction of the in vivo behavior of a variety of high- and low-metastatic human and mouse cancer cell lines and the discrimination of tumor microenvironments in the lung that were most permissive to metastasis. Using this approach, we provide what we believe to be new insights into the importance of tumor cell interactions with the stromal components of the lung microenvironment. Finally, the translational utility of this assay was demonstrated through its use in the evaluation of therapeutics at discrete time points during metastatic progression. We believe that this assay system is uniquely capable of advancing our understanding of both metastasis biology and therapeutic strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20644255      PMCID: PMC2912183          DOI: 10.1172/JCI40252

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Metastasis-associated differences in gene expression in a murine model of osteosarcoma.

Authors:  C Khanna; J Khan; P Nguyen; J Prehn; J Caylor; C Yeung; J Trepel; P Meltzer; L Helman
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

2.  Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis.

Authors:  A B Al-Mehdi; K Tozawa; A B Fisher; L Shientag; A Lee; R J Muschel
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

3.  An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential.

Authors:  C Khanna; J Prehn; C Yeung; J Caylor; M Tsokos; L Helman
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma.

Authors:  M A Cifone; I J Fidler
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

5.  Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency.

Authors:  M D Cameron; E E Schmidt; N Kerkvliet; K V Nadkarni; V L Morris; A C Groom; A F Chambers; I C MacDonald
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

6.  Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.

Authors:  Dalit Barkan; Hynda Kleinman; Justin L Simmons; Holly Asmussen; Anil K Kamaraju; Mark J Hoenorhoff; Zi-yao Liu; Sylvain V Costes; Edward H Cho; Stephen Lockett; Chand Khanna; Ann F Chambers; Jeffrey E Green
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 7.  Metastasis: recent discoveries and novel treatment strategies.

Authors:  Suzanne A Eccles; Danny R Welch
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

8.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.

Authors:  Chand Khanna; Xiaolin Wan; Seuli Bose; Ryan Cassaday; Osarenoma Olomu; Arnulfo Mendoza; Choh Yeung; Richard Gorlick; Stephen M Hewitt; Lee J Helman
Journal:  Nat Med       Date:  2004-01-04       Impact factor: 53.440

Review 9.  Novel targets with potential therapeutic applications in osteosarcoma.

Authors:  Chand Khanna
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

10.  Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  J S Rhim; D L Putman; P Arnstein; R J Huebner; R M McAllister
Journal:  Int J Cancer       Date:  1977-04-15       Impact factor: 7.396

View more
  53 in total

1.  Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.

Authors:  Ling Ren; Sung-Hyeok Hong; Qing-Rong Chen; Joseph Briggs; Jessica Cassavaugh; Satish Srinivasan; Michael M Lizardo; Arnulfo Mendoza; Ashley Y Xia; Narayan Avadhani; Javed Khan; Chand Khanna
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

Review 2.  Preclinical mouse cancer models: a maze of opportunities and challenges.

Authors:  Chi-Ping Day; Glenn Merlino; Terry Van Dyke
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

3.  Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.

Authors:  Lara H El Touny; Anthony Vieira; Arnulfo Mendoza; Chand Khanna; Mark J Hoenerhoff; Jeffrey E Green
Journal:  J Clin Invest       Date:  2013-12-09       Impact factor: 14.808

Review 4.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

5.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis.

Authors:  Jeff H Tsai; Joana Liu Donaher; Danielle A Murphy; Sandra Chau; Jing Yang
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

6.  TGF-β signaling in myeloid cells is required for tumor metastasis.

Authors:  Yanli Pang; Sudheer Kumar Gara; Bhagelu R Achyut; Zhaoyang Li; Hannah H Yan; Chi-Ping Day; Jonathan M Weiss; Giorgio Trinchieri; John C Morris; Li Yang
Journal:  Cancer Discov       Date:  2013-05-09       Impact factor: 39.397

Review 7.  Targeting dormant micrometastases: rationale, evidence to date and clinical implications.

Authors:  Robert E Hurst; Anja Bastian; Lora Bailey-Downs; Michael A Ihnat
Journal:  Ther Adv Med Oncol       Date:  2016-03       Impact factor: 8.168

8.  CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ.

Authors:  Hangyi H Yan; Jian Jiang; Yanli Pang; B R Achyut; Michael Lizardo; Xinhua Liang; Kent Hunter; Chand Khanna; Christine Hollander; Li Yang
Journal:  Cancer Res       Date:  2015-10-19       Impact factor: 12.701

9.  Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

Authors:  G Bulut; S-H Hong; K Chen; E M Beauchamp; S Rahim; G W Kosturko; E Glasgow; S Dakshanamurthy; H-S Lee; I Daar; J A Toretsky; C Khanna; A Uren
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

10.  Toward a drug development path that targets metastatic progression in osteosarcoma.

Authors:  Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.